Rekvina Laboratories is acquiring 100% of Radiant Parenterals Limited through a share swap. The deal involves issuing 46,27,750 shares for Radiant, a manufacturer of injectables, syrups, and suspensions. This inorganic growth move aims to expand Rekvina's market presence and integrate operations.
Rekvina Laboratories Acquires Radiant Parenterals in Share Swap Deal
Rekvina Laboratories is set to acquire 100% of Radiant Parenterals Limited. The company will issue 46,27,750 equity shares in a swap and 4,60,000 shares for cash. ## What just happened Rekvina Laboratories announced its plan to acquire Radiant Parenterals Limited, a company specializing in manufacturing injectables, syrups, and suspensions. The acquisition will be completed through a combination of share swap and cash preferential allotment. Rekvina will issue 46,27,750 equity shares to Radiant's existing shareholders as part of a share swap, and an additional 4,60,000 shares for cash. Radiant Parenterals is noted for its WHO-GMP and ISO 9001-2015 certifications. ## Why this matters This acquisition is a strategic move by Rekvina Laboratories to pursue inorganic growth. It aims to expand its presence in the pharmaceutical sector, integrate operations, strengthen its customer base, and increase market share. By bringing Radiant Parenterals, which has demonstrated significant revenue growth, into its fold, Rekvina intends to leverage shared resources and expertise. ## The backstory Radiant Parenterals has shown a strong revenue growth trajectory, with revenues reaching ₹31.67 crore in FY 2024-25, up from ₹17.36 crore in FY 2023-24 and ₹0.77 crore in FY 2022-23. The preferential allotment for the swap is valued at ₹4.63 crore at ₹10 per share, while the cash tranche amounts to ₹0.46 crore. ## What changes now The combined entity is expected to benefit from integrated operations and expanded market reach. Management expects to leverage shared infrastructure and expertise to enhance market position. The acquisition is subject to regulatory and shareholder approvals. ## Risks to watch Securities allotted on a preferential basis are subject to lock-in restrictions as per SEBI regulations. While the transaction is conducted at arm's length based on independent valuation, promoters hold interests in the target entity, requiring careful monitoring of related party disclosures and compliance. ## Peer comparison (No specific peer comparison data available in the filing.) ## Context metrics (time-bound) Radiant Parenterals revenue: FY24 ₹17.36 crore, FY25 ₹31.67 crore. Total shares issued: 50,87,750 (46,27,750 swap, 4,60,000 cash) at ₹10/share. ## What to track next Investors should monitor the progress of regulatory and shareholder approvals, the integration of Radiant Parenterals' operations, and the impact on Rekvina's overall market share and financial performance. Compliance with SEBI lock-in regulations for the allotted shares will also be key. Reader Takeaway: Inorganic growth via share swap to expand market share and integrate operations; track post-acquisition integration progress.
